| 1 |
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
John Patrick Thornhill et al. · New England Journal of Medicine
Open access |
21 Jul 2022 |
2,219 |
| 2 |
Developments in the MPI‐M Earth System Model version 1.2 (MPI‐ESM1.2) and Its Response to Increasing CO 2
Thorsten Mauritsen et al. · Journal of Advances in Modeling Earth Systems
Open access |
13 Jan 2019 |
1,619 |
| 3 |
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
Alison J. Rodger et al. · The Lancet
Open access189 authors |
2 May 2019 |
1,029 |
| 4 |
The Max Planck Institute Grand Ensemble: Enabling the Exploration of Climate System Variability
Nicola Maher et al. · Journal of Advances in Modeling Earth Systems
Open access |
4 Jun 2019 |
583 |
| 5 |
Accuracy assessment of global barotropic ocean tide models
Detlef B. Stammer et al. · Reviews of Geophysics
Open access |
18 Jul 2014 |
562 |
| 6 |
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink et al. · The Lancet
Open access |
8 Jan 2013 |
552 |
| 7 |
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis et al. · The Lancet
|
24 Jul 2017 |
509 |
| 8 |
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Frits van Rhee et al. · Blood
Open access |
4 Sep 2018 |
427 |
| 9 |
Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study
Hans‐Jürgen Stellbrink, Chloe M. Orkin, José Ramón Arribas et al. · Clinical Infectious Diseases
|
9 Sep 2010 |
412 |
| 10 |
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
Paul Edward Sax, Anton Louis Pozniak, Marisa Montes et al. · The Lancet
|
Sep 2017 |
406 |
| 11 |
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
Mark Richard Nelson, Christine Katlama, Joan Montaner et al. · AIDS
|
Jun 2007 |
353 |
| 12 |
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
Sorana Segal‐Maurer, Edwin DeJesus, Hans‐Jürgen Stellbrink et al. · New England Journal of Medicine
Open access |
11 May 2022 |
329 |
| 13 |
Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
Christian Hoffmann, Tanya Welz, Michael Sabranski et al. · HIV Medicine
|
10 Nov 2016 |
290 |
| 14 |
Measuring Global Ocean Heat Content to Estimate the Earth Energy Imbalance
Benoît Meyssignac et al. · Frontiers in Marine Science
Open access |
20 Aug 2019 |
266 |
| 15 |
HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans
Christoph D. Spinner, Christoph Boesecke, Alexander Zink et al. · Infection
|
15 Oct 2015 |
248 |
| 16 |
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients
Georg Härter, Christoph D. Spinner, Julia Roider et al. · Infection
Open access |
11 May 2020 |
245 |
| 17 |
Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study
Frank A. Post, Graeme J Moyle, Hans Jürgen Stellbrink et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes
Open access |
27 Apr 2010 |
220 |
| 18 |
Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study
Elchonon M. Berkowitz, Graeme J Moyle, Hans‐Jürgen Stellbrink et al. · The Journal of Infectious Diseases
Open access |
3 Nov 2014 |
217 |
| 19 |
Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia
Helmut J.F. Salzer, Guido Schäfer, Martin Hoenigl et al. · Respiration
|
2018 |
201 |
| 20 |
Global temperature modes shed light on the Holocene temperature conundrum
Jürgen Bader, Johann H. Jungclaus, N. A. Krivova et al. · Nature Communications
Open access |
18 Sep 2020 |
189 |
| 21 |
Skin Lesion Classification Using CNNs With Patch-Based Attention and Diagnosis-Guided Loss Weighting
Nils Gessert, Thilo Sentker, Frederic Madesta et al. · IEEE Transactions on Biomedical Engineering
Open access |
9 May 2019 |
180 |
| 22 |
HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe
Patrick Ingiliz, Thomas Martin, Alison J. Rodger et al. · Journal of Hepatology
Open access |
18 Sep 2016 |
174 |
| 23 |
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV
Christian Hoffmann, José L. Casado, Georg Härter et al. · HIV Medicine
Open access |
27 Dec 2020 |
166 |
| 24 |
Dolutegravir in antiretroviral-naive adults with HIV-1
Hans-Jürgen Stellbrink, Jacques Reynes, Adriano Lazzarin et al. · AIDS
Open access |
22 Mar 2013 |
163 |
| 25 |
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0
Lene Ryom, AG Cotter, R De Miguel et al. · HIV Medicine
Open access |
3 Sep 2020 |
155 |
| 26 |
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study
Chloe M. Orkin, Enrique Bernal, Darrell H. S. Tan et al. · The Lancet HIV
|
16 Oct 2021 |
145 |
| 27 |
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
Calvin J. Cohen, Jean‐Michel Molina, Isabel Cassetti et al. · AIDS
|
4 Dec 2012 |
139 |
| 28 |
PAIP 2019: Liver cancer segmentation challenge
Yoo Jung Kim et al. · Medical Image Analysis
Open access |
8 Oct 2020 |
128 |
| 29 |
A High‐End Estimate of Sea Level Rise for Practitioners
Roderik S. W. van de Wal et al. · Earth s Future
Open access |
22 Oct 2022 |
127 |
| 30 |
The Trauma Related Shame Inventory: Measuring Trauma-Related Shame Among Patients with PTSD
Tuva Øktedalen, Knut Arne Hagtvet, Asle Hoffart et al. · Journal of Psychopathology and Behavioral Assessment
|
21 Apr 2014 |
124 |
| 31 |
Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials
Kristine Mace Erlandson, Christoph C Carter, Kathleen M. Melbourne et al. · Clinical Infectious Diseases
Open access |
11 May 2021 |
121 |
| 32 |
Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors
Christian Hoffmann, Josep Maria Llibre · Aids Reviews
|
18 Mar 2019 |
115 |
| 33 |
Clinical characteristics of monkeypox virus infections among men with and without HIV : A large outbreak cohort in Germany
Christian Hoffmann et al. · HIV Medicine
Open access |
4 Sep 2022 |
114 |
| 34 |
Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada
Kevin Robertson, Carmen Bayón, Jean‐Michel Molina et al. · AIDS Care
Open access |
16 Jul 2014 |
113 |
| 35 |
Late presentation for HIV diagnosis and care in G ermany
Alexander Zoufaly, Matthias an der Heiden, U Marcus et al. · HIV Medicine
|
7 Nov 2011 |
101 |
| 36 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
Anton Louis Pozniak, Martin H. Markowitz, Anthony Mills et al. · The Lancet Infectious Diseases
Open access |
4 Jun 2014 |
100 |
| 37 |
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk
José M. Gatell, Lambert Assoumou, Graeme J Moyle et al. · AIDS
Open access |
6 Nov 2017 |
93 |
| 38 |
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection
Álvaro Humberto Borges, Jacqueline Neuhaus, Abdel G. Babiker et al. · Clinical Infectious Diseases
Open access |
8 Sep 2016 |
93 |
| 39 |
SKIM, a Candidate Satellite Mission Exploring Global Ocean Currents and Waves
Fabrice Ardhuin et al. · Frontiers in Marine Science
Open access |
30 Apr 2019 |
92 |
| 40 |
Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease
Christian Hoffmann, Holger Schmid, Markus Matthias Müller et al. · Blood
|
21 Jul 2011 |
92 |
| 41 |
Soil carbon sequestration simulated in CMIP6-LUMIP models: implications for climatic mitigation
Akihiko Ito, Tomohiro Hajima, David M. Lawrence et al. · Environmental Research Letters
Open access |
10 Nov 2020 |
90 |
| 42 |
Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort
Álvaro Humberto Borges et al. · Clinical Infectious Diseases
Open access |
16 Feb 2017 |
90 |
| 43 |
Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada
Christian Hoffmann, Eva Wolf · Infection
Open access |
24 Oct 2020 |
89 |
| 44 |
Framework for High‐End Estimates of Sea Level Rise for Stakeholder Applications
Detlef B. Stammer, Roderik S. W. van de Wal, Robert J. Nicholls et al. · Earth s Future
Open access |
28 Jun 2019 |
84 |
| 45 |
German‐Austrian guidelines on anal dysplasia and anal cancer in HIV‐positive individuals: prevention, diagnosis, and treatment
Stefan Eßer, Alexander Kreuter, Mark Oette et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft
|
27 Nov 2015 |
69 |
| 46 |
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study
Graham H.R. Smith et al. · Open Forum Infectious Diseases
Open access |
25 Aug 2021 |
64 |
| 47 |
96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study
Graeme J Moyle, Hans‐Jürgen Stellbrink, Juliet Elizabeth Compston et al. · Antiviral Therapy
|
31 Jul 2013 |
61 |
| 48 |
Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients
Josep M. Gatell, Javier O Morales‐Ramirez, Debbie P. Hagins et al. · Journal of the International AIDS Society
Open access |
Nov 2014 |
60 |
| 49 |
Morbidity in older HIV-infected patients: impact of long-term antiretroviral use.
Giovanni Guaraldi, Manyu Prakash, Christiane Moecklinghoff et al. · PubMed
Open access |
Apr 2015 |
59 |
| 50 |
Clinical characteristics and comparison of longitudinal qPCR results from different specimen types in a cohort of ambulatory and hospitalized patients infected with monkeypox virus.
Dominik Sebastian Nörz et al. · Journal of Clinical Virology
Open access |
11 Aug 2022 |
58 |